Profile
Mr. Patrick E.
Dolezal is a Senior Research Analyst at LifeSci Capital LLC.
He focuses on emerging biotechnology and pharmaceutical companies.
His coverage universe includes a diverse range of therapeutic areas, which include gene therapy, gene editing, and hepatology.
He received his undergraduate degree from Indiana University and a graduate degree from New York University.
Patrick Dolezal active positions
| Companies | Position | Start |
|---|---|---|
LifeSci Capital LLC
 LifeSci Capital LLC Investment Banks/BrokersFinance LifeSci Capital LLC is a full-service investment bank that offers financial and strategic advisory services, institutional outreach, and research to leading life sciences companies. The private company is based in New York, NY. The company's team of investment bankers has extensive experience at bulge bracket and specialty investment banks. LifeSci Capital's highly regarded team of analysts generates differentiated, proprietary research and covers companies across all major therapeutic areas. The company was founded in 2013 by Andrew Ian McDonald and Michael Yehuda Rice. Andrew Ian McDonald has been the CEO since 2013. | Analyst-Equity | 31/05/2015 |
Training of Patrick Dolezal
| New York University | Graduate Degree |
| Indiana University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 1 |
|---|---|
LifeSci Capital LLC
LifeSci Capital LLC Investment Banks/BrokersFinance LifeSci Capital LLC is a full-service investment bank that offers financial and strategic advisory services, institutional outreach, and research to leading life sciences companies. The private company is based in New York, NY. The company's team of investment bankers has extensive experience at bulge bracket and specialty investment banks. LifeSci Capital's highly regarded team of analysts generates differentiated, proprietary research and covers companies across all major therapeutic areas. The company was founded in 2013 by Andrew Ian McDonald and Michael Yehuda Rice. Andrew Ian McDonald has been the CEO since 2013. | Finance |
- Stock Market
- Insiders
- Patrick Dolezal
